Boston Scientific Forgoes Cost Cuts, Predicting Stent/ICD Market Recovery
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific will maintain current cost structures in its drug-eluting stent and cardiac rhythm management businesses in the near term, anticipating both markets will soon recover from a 2006 slump